Want to see AQST full AI Analyst Report?
AQST Stock Chart & Stats
$5.16
$0.06(1.77%)
At close: 4:00 PM EDT
$5.16
$0.06(1.77%)
Day’s Range― - ―
52-Week Range$2.93 - $7.55
Previous CloseN/A
Volume1.45M
Average Volume (3M)3.33M
Market Cap
$671.49M
Enterprise Value$570.57
Total Cash (Recent Filing)$98.49M
Total Debt (Recent Filing)$59.00M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 09, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding125,511,650
10 Day Avg. Volume2,641,599
30 Day Avg. Volume3,329,592
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)-23.41
Price to Sales (P/S)17.69
P/FCF Ratio-14.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside74.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$49.92M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained year-over-year growth indicates stronger demand across manufacturing, supply, licensing, and royalty activities. Continued expansion of these revenue streams can improve operating leverage and reduce reliance on a single future product launch.
Anaphylm Development ProgressThe completed studies directly address deficiencies cited in the FDA response and strengthen Anaphylm’s approval case. If accepted, the product could extend Aquestive’s proprietary film technology into a large, differentiated emergency-allergy market.
Improving Operating LeverageMaterial improvement in adjusted EBITDA losses, alongside solid gross margins, suggests better cost absorption as revenue scales. This supports a path toward improved cash efficiency if commercial growth continues and launch spending remains controlled.
Bears Say
Persistent Cash Burn And LossesNegative operating and free cash flow show that the current business does not yet fund its operations. Continued losses may require additional capital before Anaphylm or other pipeline products generate meaningful commercial cash flow.
Weak Balance SheetNegative equity and meaningful debt constrain financial flexibility and increase dependence on lenders or equity markets. If operating losses persist, refinancing terms, dilution, or restrictive financing conditions could weaken long-term shareholder economics.
Approval And Launch Funding RiskAnaphylm’s commercial contribution depends on regulatory approval, payer adoption, and contingent launch financing. Delays, unfavorable coverage, or unmet funding conditions could postpone commercialization and extend the company’s cash-burn period.
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $2.93 and its highest was $7.55 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Aquestive Therapeutics’s market cap is $671.49M.
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 64 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.105 by -$0.075.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 125,511,650 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.105. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Currently, no hedge funds are holding shares in AQST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (74.42% Upside)
$9.00 (74.42% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 775.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $311.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
40.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
AQST Company Deck
AQST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress on the Anaphylm program (completed human factors and PK studies, strong human factors improvements, favorable PD data) and solid financial execution (significant year-over-year revenue growth, materially improved adjusted EBITDA, strong cash balance and a new $150M debt facility). The principal negatives were a large one-time debt extinguishment charge that widened reported Q2 net loss, higher Q2 SG&A from legal and severance costs, a few residual human factors issues (very small), and remaining uncertainty around FDA review timing, payer coverage and reliance on contingent launch funding. On balance, operational, clinical and liquidity positives meaningfully outweigh the near-term financial and execution risks.View all AQST earnings summariesAQST Stock 12 Month Forecast
Average Price Target
$9.00
▲(74.42% Upside)
Technical Analysis
Ownership Overview
2.25% Insiders
9.16% Mutual Funds
23.67% Other Institutional Investors
55.35% Public Companies and
Individual Investors